# Remedy

#### **Company report**

2/14/2022



Atte Riikola +358 44 593 4500 atte.riikola@inderes.fi

✓ Inderes corporate customer



This report is a summary translation of the report "Pitkää peliä pelaavan sijoittajan ostopaikka" published on 02/14/2022 at 08:05 am

### Buying opportunity for those who play the long game

As we expected, Remedy's Q4 result was exceptionally strong, partially because of timing-related factors. Thanks to the company's outlook and the Tencent agreement for the Vanguard projects, the earnings growth outlook for 2023-2025 starts to clear up. Materializing the earnings potential of the games currently under development seem to focus more strongly on 2024-2025, in contrast to our previous estimates (2023-2024). Thus, a bit of patience is required. Then, the share's valuation becomes so low that we consider the expected return very attractive for investors who play the long game. Thus, we reiterate our Buy recommendation and EUR 50.0 target price for Remedy.

#### Exceptionally strong finish for the year, as expected

Remedy's Q4 revenue grew by 39% to EUR 19.8 million which exceeded our EUR 18.8 million estimate. As expected, growth came from development fees (Q4'21: 92% of revenue), when the development, license and distribution agreement made with Tencent for the Vanguard project in late 2021 supported revenue development. In Q4, royalty revenue (Q4'21: 1.5 MEUR) was generated only from Control, and Alan Wake Remastered that was released in October didn't yet cover its production and marketing budget. We expect AWR to start showing up in royalty revenue in the upcoming quarters. In Q4, Remedy's operating profit was EUR 11.3 million (Q4'20: 6.6 MEUR) and was very close to our estimate (11.1 MEUR). Remedy's cost structure is largely fixed, so there can be major swings in operating profit due to revenue timing. The retroactively paid Vanguard development fees brought Q4 profitability (EBIT-% 57%) to an exceptionally strong level.

#### Earnings growth outlook for 2023-2025 is shaping up

In its outlook, Remedy expects its revenue to grow and its operating profit to be at a lower level than in 2021. Remedy is currently working on 4 major game projects. Moving these forward in the production pipeline requires more investments in recruitment and external game development. According to Remedy, the visibility to the upcoming titles is very good and the company's capabilities to take the projects to the release phase are stronger than ever. Remedy's ongoing game projects seem to be higher in budget and longer in development time than we had anticipated. Therefore, we have re-evaluated our expectations regarding costs and the timing of game releases, which is visible in lowered earnings estimates for 2022-2023. Similarly, visibility and our confidence in the earnings estimates for 2024-2025 have improved, as Remedy confirmed that the upcoming major game titles will be released in 2023-2025. In our estimates, with the releases of Alan Wake 2 (2023), Condor (2024), Vanguard (2024), and Heron (2025), Remedy's earnings growth will be strong, supported by growing royalty revenue.

#### Current market nervousness offers a purchase opportunity for those in for the long game

In our estimates, royalties from Remedy's presently ongoing game projects take largely place in 2024-2025, when we expect the company's revenue (82.9 and 98.5 MEUR) and earnings (EBIT: 29.1 and 37.2 MEUR) take a significant step upward. With our estimates, the share's EV/EBIT ratios (2024e-2025e: 12x-9x) go down to a very attractive level even with moderately successful game releases. In addition, the investor gets the option of a hit game that strikes gold. However, we realize that with the 2022 earnings, Remedy's valuation (EV/EBIT 34x) is tight and the market sentiment that weakened early in the year can cause pressure around the share. The time horizon of investors typically shortens, when uncertainty grows but we consider the current market nervousness as a buying opportunity for patient investors who play the long game.

#### Recommendation



#### **Key figures**

	2021	2022e	2023e	<b>2024</b> e
Revenue	44.7	47.4	60.9	82.9
growth-%	9%	6%	28%	36%
EBIT adj.	14.7	11.5	15.8	29.1
EBIT-% adj.	32.9 %	24.3 %	26.0 %	35.1 %
Net Income	10.8	9.1	12.6	23.2
EPS (adj.)	0.88	0.68	0.93	1.71
P/E (adj.)	45.3	49.6	35.9	19.6
P/B	6.0	4.8	4.3	3.6
Dividend yield-%	0.4 %	0.6 %	0.8 %	0.9 %
EV/EBIT (adj.)	32.3	34.1	24.1	12.3
EV/EBITDA	29.9	29.5	15.1	8.6
EV/S	10.6	8.3	6.3	4.3
<b>2</b>				

Source: Inderes


#### Guidance

(New guidance)

"Remedy expects its revenue to grow and operating profit to be on a lower level than in 2021. "

#### Share price





**Revenue and EBIT %** 

#### **EPS** and dividend



#### Value drivers

**M** 

- Attractive position in value chain considering industry trends and consolidation
- Three own game brands that are developed into new games with world-class partners
- Multi-project model creates continuity and disperses risks
- Strong track record of developing successful games
- Own game engine and game development tools create scalability and a competitive advantage



- Failure or delays in game projects
- Dependency on publishing partners
- Commercial failure of upcoming games
- Technology and market trends

Valuation	2022e	2023e	2024e
Share price	33.5	33.5	33.5
Number of shares, millions	13.4	13.5	13.6
Market cap	449	449	449
EV	393	381	358
P/E (adj.)	49.6	35.9	19.6
P/E	49.6	35.9	19.6
P/FCF	81.0	31.1	17.1
P/B	4.8	4.3	3.6
P/S	9.5	7.4	5.4
EV/Sales	8.3	6.3	4.3
EV/EBITDA	29.5	15.1	8.6
EV/EBIT (adj.)	34.1	24.1	12.3
Payout ratio (%)	29.6 %	26.8 %	17.6 %
Dividend yield-%	0.6 %	0.8 %	0.9 %



## Exceptionally strong finish for the year, as expected

#### Strong growth in Q4

Remedy's Q4 revenue grew by 39% to EUR 19.8 million which exceeded our EUR 18.8 million estimate. In particular, the development, license and distribution agreement with Tencent for the Vanguard project supported revenue growth. Development fees were retroactively recognized based on development work that had already been done (our estimate ca. 11 MEUR). Additionally, the Alan Wake 2 project generated increasing amounts of development fees, as the project is in full production phase. Remedy also said that it had agreed upon expanding the AW2 budget with Epic, which also generated more development fees for Q4. In total, the development fees (Q4'21: 18.3 MEUR) made up 92% of revenue.

In Q4, royalty revenue (Q4'21: 1.5 MEUR) was generated only from Control, and Alan Wake Remastered that was released in October didn't yet cover its production and marketing budget. Remedy and Epic Games split the profits evenly once development and marketing costs financed by Epic have been covered. According to Remedy, AWR has been well received by both game critics and players, and its sales have progressed in line with Remedy's expectations. With our estimated EUR 8 million budget for the game roughly half a million copies must be sold to cover the costs. We expect AWR to start generating royalty revenue for Remedy from Q1'22 onward. In the coming years, the share of highprofit royalties of Remedy's revenue will increase significantly with new game releases, which supports profitability development.

## Q4 was exceptionally good thanks to Vanguard development fees

In Q4, Remedy's operating profit was EUR 11.3 million (Q4'20: 6.6 MEUR) and was very close to our estimate (11.1 MEUR). Remedy's cost structure is largely fixed, so there can be major swings in quarterly operating profit due to timing of development fees and royalties. The retroactively paid Vanguard development fees brought Q4 profitability (EBIT-% 57%) to an exceptionally strong level. Although the Q4 figures were supported by timing-related factors, they tell something about the attractive growth and profitability potential of Remedy's business model.

EPS for 2021 was EUR 0.81, of which Remedy's board proposes EUR 0.17 to be paid as a dividend (2020: 0.15 EUR). Currently, the role of dividend is miniscule in Remedy's investment profile.

Remedy's cash situation is very strong after the directed share issue in early 2021. At the end of Q4, cash and financial securities amounted to EUR 55.6 million. Remedy has invested EUR 7 million of its cash position in liquid securities to neutralize the effect of negative interest rates on financial costs. However, the net cash reported by the company (Q4'21: 48.6 MEUR) doesn't take these securities into account, which is important to bear in mind.

Estimates MEUR / EUR	Q4'20 Comparison	Q4'21 Actualized	Q4'21e Inderes	Q4'21e Consensus	Consensus Low High	Difference (%) Act. vs. inderes	2021 Act
Revenue	14,2	19,8	18,8			5 %	44,7
EBITDA	7,0	11,6	11,4			2 %	15,9
EBIT (adj.)	6,6	11,3	11,1			2 %	14,7
EPS (reported)	0,43	0,68	0,68			0 %	0,81
DPS	0,15	0,17	0,20			-15 %	0,17
Revenue growth-%	-	39,4 %	32,4 %			7 pp	8,9 %
EBIT-% (adj.)	46,8 %	56,9 %	59,0 %			-2,1 pp	32,9 %

## **Progress with strategy and game projects**

#### In the future, revenue from Smilegate subcontracting comes mainly from royalties instead of development fees

Regarding the Smilegate cooperation, the revenue flow will be be lower in terms of development fees, as Remedy allocated its developers to other ongoing projects last year. We believe that Remedy has many opportunities for different cooperations, but we believe that the company will primarily invest in projects that are based on its own game brands. In these, the long-term value creation potential is considerably greater and Remedy's strong financial position allows the company to make required investments in the projects and to bear risks associated to them.

In the future, it's possible that Remedy receives certain royalty payments depending on the success of Crossfire X and Crossfire HD, for which the company has developed story modes modes. Crossfire X was released for Xbox 2/10/2022 and the story mode of Crossfire HD was released in China in November 2021.

#### New Control projects progressing as planned

In June, Remedy signed a co-release and codevelopment deal of the new Condor project with 505 Games, with an initial budget of ca. EUR 25 million. Condor is a four player PvE game (player vs. environment) that takes place in the Control universe. The development and marketing investments and net earnings will be evenly split between 505 Games and Remedy. Condor is currently in the proof-ofconcept stage and is already generating some development fees to Remedy.

Furthermore, Remedy and 505 Games are

developing another larger-budget Control game (codename Heron), which we expect to be a sequel for the original game. We estimate Heron's development budget to be around EUR 40 million and the development deal to be similar to that of the Condor project. Heron entered concept stage in Q4.

## Partnering up with Tencent on the Vanguard project

The development, license and distribution agreement made with Tencent for the multiplayer game project Vanguard in late December indicates that the project is progressing well. Vanguard is currently in the proof-of-concept stage and Remedy comments that it's gradually increasing the team size (Q3'21 > 35 people).

According to Remedy, the project has a budget of an AAA game (30-60 MEUR) which is a typical budget size for the company, even though defining the budget is more difficult, as development continues for years after the release in the live stage. Remedy and Tencent finance the development together, but the exact split of the development budget hasn't been disclosed. Furthermore, Tencent localizes the game for select Asian markets and covers the costs related to that. We expect the project budget to initially be over EUR 40 million and Tencent to finance roughly 60% of it.

Remedy and Tencent bear the game's development and operating costs in their respective geographical areas, sharing part of the income with the other party after the development costs have been covered. This means that for the first time in its history, Remedy acts as the publisher of its game and is responsible for, e.g., marketing and player acquisition in the Western market. As the publisher, the company will likely collect more of the Western market's income, whereas Tencent's share is bigger in Asia and China.

In the agreement, Remedy has also licensed Tencent to global rights for developing and publishing a mobile version of the game. Tencent bears the development and publishing costs of the mobile version. For the mobile version, the companies have agreed upon a separate revenue share model. To our understanding, the development of the mobile version depends on Vanguard's reception on consoles and PC. At this point, we consider the mobile version a risk-free and positive option for Remedy, which realizes if Vanguard is successful.

## Earnings growth outlook for 2023-2025 is shaping up

## Remedy's growth story takes one more year of patience

In its guidance, Remedy expects its revenue to grow and its operating profit to be at a lower level than in 2021. Remedy is currently working on 4 major game projects. Moving these forward in the production pipeline requires more investments in recruitment and external game development. According to Remedy, the visibility to the upcoming titles is very good and the company's capabilities to take the projects to the release phase are stronger than ever.

Remedy's ongoing game projects seem to be higher in budget and longer in development time than we had anticipated. Therefore, we have re-evaluated our expectations regarding costs and the timing of game releases, which is visible in lowered earnings estimates for 2022-2023. Similarly, visibility and our confidence in the earnings estimates for 2024-2025 have improved, as Remedy confirmed that the upcoming major game titles will be released in 2023-2025. Keeping in mind that games start to generate royalties with a delay after costs have been covered, it would seem like that materializing the growth potential of the current game projects would take place in 2024-2025. Previously, we had assumed that the growth leap would happen in 2023-2024-

#### Estimates for the coming years

Precise estimation of Remedy's earnings development in coming years is challenging due to the nature of the company's business model. We outline Remedy's revenue drivers for 2022-2025 on the following page. The development fees of the games currently under development create a solid base for revenue estimates, but the visibility to royalty forecasts is weak. In the big picture, we estimate that Remedy's upcoming games will have a reasonably good success, but we see potential for significantly better performance.

We estimate Remedy's revenue to grow by 6% this year, mainly driven by AWR and Crossfire royalties. In our estimates, most of revenue (77%) still comes from development fees. Given the growing number of recruits and other costs, we estimate operating profit to decrease to EUR 11.5 million. In 2023, we expect Remedy's revenue growth to accelerate to 28% and operating profit to be EUR 15.8 million with the release of Alan Wake 2. At the moment, we estimate that a significant share of AW2 royalties will be generated in 2024-2025.

We expect Vanguard and Condor to be released in 2024. By then, Remedy will have at least one new significant ongoing game project, which generates development fees. In our estimates, Remedy's 2024 revenue will grow by 36% to EUR 82.9 million, driven by royalties. High-margin royalties also support profitability (EBIT: 35%) and we expect operating profit to grow to EUR 29.1 million.

We estimate that the Heron project (Control 2) will released in 2025 and that in total, Remedy will get revenue from at least 8 games that have already been released or are currently being developed. In our estimates, revenue grows by 19% to EUR 98.5 million and operating profit by 28% to EUR 37.2 million, which represents a 38% EBIT margin. When the strategy progresses, we believe that Remedy has good preconditions to continue growing after this too.

Estimate revisions MEUR / EUR	2021 Old	2021 Act	Change %	2022e Old	2022e New	Change %	2023e Old	2023e New	Change %
Revenue	43,7	44,7	2 %	46,8	47,4	1%	68,3	60,9	-11 %
EBITDA	15,7	15,9	1 %	16,5	13,3	-20 %	35,4	25,3	-28 %
EBIT (exc. NRIs)	14,5	14,7	1 %	14,4	11,5	-20 %	24,3	15,8	-35 %
EBIT	14,5	14,7	1 %	14,4	11,5	-20 %	24,3	15,8	-35 %
PTP	13,3	13,5	1 %	14,3	11,3	-21 %	24,2	15,7	-35 %
EPS (excl. NRIs)	0,88	0,88	-1 %	0,88	0,68	-23 %	1,48	0,93	-37 %
DPS	0,20	0,17	-15 %	0,25	0,20	-20 %	0,30	0,25	-17 %

## Strategy in light of game projects

s =low revenue

**\$\$** =medium revenue

**\$\$\$** =considerable revenue

	2020	2021	2022	2023	2024	2025
Crossfire	Development fees	Development fees	Royalties	Royalties	Royalties	Royalties
Jossine	\$\$\$	\$\$\$	\$/\$\$	\$/\$\$	\$/\$\$	\$/\$\$
) a mtwal	Royalties	Royalties	Royalties	Royalties	Royalties	Royalties
Control	\$\$\$	\$\$\$	\$\$	\$/\$\$	\$/\$\$	\$
pic projects	Development fees	Development fees and Alan Wake Remastered release	Development fees + royalties	Alan Wake 2 release	Royalties	Royalties
pic projects	\$\$\$	\$\$\$	\$\$\$	\$\$\$	\$\$\$	\$\$\$
anguard	Conceptualization / pre-	Development and distribution agreementl with Tencent	Development fees	Development fees	Release	Royalties
<b>9</b>	production	\$\$\$	\$\$\$	\$\$\$	\$\$\$	\$\$\$
		Development fees	Development fees	Development fees	Release	Royalties
Condor		\$	\$\$/\$\$\$	\$\$/\$\$\$	\$\$\$	\$\$\$
Control 2		Concentualization	Development fees	Development fees	Development fees	Release
Heron)		Conceptualization	\$\$/\$\$\$	\$\$/\$\$\$	\$\$\$	\$\$\$
lext game			Concentration	Development fees	Development fees	Development fees
projects			Conceptualization	\$\$/\$\$\$	\$\$\$	\$\$\$

## Valuation

## Valuation is attractive in light of long-term growth story

Over this decade, the ability of Remedy's team to launch high-guality games efficiently, favorable market trends and an attractive position in the value chain offer the company extremely good preconditions to grow into a significantly larger game house than currently. A multi-project model that has been built with controlled risks and is well-managed also bring attractive optionality from the viewpoint of the return/risk ratio of the company's business model. We believe the likelihood of complete failures in game projects is extremely low but one of future projects can become an actual hit game. The revenue potential of a single game varies from tens of millions to well over hundreds of million euros, so the range of possible outcomes is wide. With successful ramp-up of the multi-project model, the release rate of games also guickens and the number of "success options" increases. We estimate that even with only relatively well succeeding games, Remedy's growth outlook is good far into the future.

Remedy's P/E multiples for 2022-2023 are 50x and 46x and EV/EBIT multiples that take into consideration the strong net cash is 34x and 24x. The multiples, especially for 2021, are high and reflect the considerable earnings growth expectations loaded into the share. However, Remedy is still only at the beginning of its growth path and the earnings level of the next few years does not provide the full picture of the company's potential. Thus, we feel the valuation should be examined in light of the company's longterm growth outlook. However, we point out that the tight valuation in the short term does not leave much room for a bigger fracture in the growth story. In our estimates, royalties from Remedy's presently ongoing game projects take largely place in 2024-2025, when we expect the company's revenue and earnings go up a significant step. With our estimates, the EV/EBIT multiples (2024e-2025e: 12x-9x) go down to a very attractive level, as we expect Remedy's growth outlook to remain strong after that too. Moreover, EV/Sales ratios (4x-3x) go down to a low level, considering Remedy's growth and profitability potential.


Our target price corresponds to 20x-15x EV/EBIT multiples with our 2024-2025 estimates, which we consider moderate, if Remedy's growth story continues on track. However, we realize that the market sentiment that weakened early in the year can cause pressure around Remedy's share, because the time horizon of investors typically shortens, when uncertainty grows. We consider the current market nervousness a good purchase opportunity for patient investors who are in for the long game.

Valuation	2022e	2023e	2024e
Share price	33.5	33.5	33.5
Number of shares, millions	13.4	13.5	13.6
Market cap	449	449	449
EV	393	381	358
P/E (adj.)	49.6	35.9	19.6
P/E	49.6	35.9	19.6
P/FCF	81.0	31.1	17.1
P/B	4.8	4.3	3.6
P/S	9.5	7.4	5.4
EV/Sales	8.3	6.3	4.3
EV/EBITDA	29.5	15.1	8.6
EV/EBIT (adj.)	34.1	24.1	12.3
Payout ratio (%)	29.6 %	26.8 %	17.6 %
Dividend yield-%	0.6 %	0.8 %	0.9 %
<b>a</b>			

### Valuation table

Valuation	2018	2019	2020	2021	2022e	2023e	<b>2024</b> e	2025e
Share price	6.70	11.5	39.0	39.7	33.5	33.5	33.5	33.5
Number of shares, millions	12.1	12.1	12.1	13.3	13.4	13.5	13.6	13.7
Market cap	81	138	471	528	449	449	449	449
EV	61	122	451	475	393	381	358	327
P/E (adj.)	>100	26.4	45.6	45.3	49.6	35.9	19.6	15.4
P/E	>100	26.4	45.6	49.0	49.6	35.9	19.6	15.4
P/FCF	neg.	neg.	82.2	15.6	81.0	31.1	17.1	12.7
P/B	3.6	5.2	13.3	6.0	4.8	4.3	3.6	3.0
P/S	4.0	4.4	11.5	11.8	9.5	7.4	5.4	4.6
EV/Sales	3.0	3.9	11.0	10.6	8.3	6.3	4.3	3.3
EV/EBITDA	55.2	16.6	31.5	29.9	29.5	15.1	8.6	6.4
EV/EBIT (adj.)	>100	18.7	34.0	32.3	34.1	24.1	12.3	8.8
Payout ratio (%)	226.8 %	25.4 %	19.0 %	21.0 %	<b>29.6</b> %	<b>26.8</b> %	<b>17.6</b> %	<b>18.4</b> %
Dividend yield-%	1.5 %	1.0 %	0.4 %	0.4 %	0.6 %	0.8 %	0.9 %	<b>1.2</b> %

Source: Inderes





EV/EBIT

EV/Sales



## Peer group valuation

Peer group valuation	Share price	Market cap	EV	EV/	EBIT	EV/E	BITDA	EV	//S	P/E	
Company		MEUR	MEUR	2022e	2023e	2022e	2023e	2022e	2023e	2022e	2023e
Frontier Developments PLC	1320.0	621	607	53.6	25.3	14.6	10.5	4.6	3.7	60.7	28.5
Embracer Group		8342	7376	17.2	11.6	12.4	7.1	5.0	2.8		
Starbreeze AB	1.1	74	67	22.2				5.6			
CD Projekt SA	178.0	4012	3713	32.4	36.2	26.6	28.1	15.0	15.5	36.4	44.1
Paradox Interactive AB	205.4	2057	2014	32.6	27.8	18.0	14.1	11.7	9.4	42.8	36.5
Koei Tecmo Holdings	4185.0	5329	5057	19.0	17.5	18.7	17.2	8.8	8.0	19.4	18.2
Team17 Group PLC	700.0	1209	1132	25.2	23.1	22.3	20.1	8.1	7.6	32.2	29.8
Playway SA	336.0	496	461	10.5	9.6	10.5	9.6	7.0	6.3	14.0	12.4
11 Bit Studios SA	553.0	293	265	153.8	9.6	68.0	6.7	19.7	4.5	125.7	11.6
Enad Global 7	33.9	279	275	17.6	14.7	6.5	5.8	1.7	1.6	31.6	25.1
Tinybuild Inc	195.5	474	420	20.5	17.9	19.1	16.9	7.3	6.7	30.8	26.8
Remedy (Inderes)	33.5	449	393	34.1	24.1	29.5	15.1	8.3	6.3	49.6	35.9
Average				36.8	19.3	21.7	13.6	8.6	6.6	43.7	25.9
Median				22.2	17.7	18.3	12.3	7.3	6.5	32.2	26.8
Diff-% to median				<b>53</b> %	<b>36</b> %	<b>61</b> %	<b>22</b> %	<b>14</b> %	<b>-3</b> %	<b>54</b> %	<b>34</b> %

Source: Thomson Reuters / Inderes. NB: The market cap Inderes uses does not consider own shares held by the company.

## **Income statement**

Income statement	2019	2020	Q1'21	Q2'21	Q3'21	Q4'21	2021	Q1'22e	Q2'22e	Q3'22e	Q4'22e	2022e	2023e	<b>2024</b> e	2025e
Revenue	31.6	41.1	8.1	9.4	7.4	19.8	44.7	10.1	10.7	12.5	14.1	47.4	60.9	82.9	98.5
Development fees	22.1	26.0	6.1	6.1	5.3	18.3	35.8	7.9	7.9	9.6	11.0	36.4	37.9	32.1	32.0
Royalties	9.5	15.0	2.0	3.3	2.1	1.5	8.9	2.2	2.8	2.9	3.1	11.0	23.0	50.8	66.5
EBITDA	7.4	14.3	1.1	2.6	0.6	11.6	15.9	1.5	1.9	4.5	5.4	13.3	25.3	41.7	50.9
Depreciation	-0.8	-1.1	-0.3	-0.3	-0.3	-0.3	-1.2	-0.5	-0.5	-0.5	-0.5	-1.8	-9.5	-12.5	-13.7
EBIT (excl. NRI)	6.5	13.2	0.9	2.3	0.3	11.3	14.7	1.1	1.5	4.0	4.9	11.5	15.8	29.1	37.2
EBIT	6.5	13.2	0.9	2.3	0.3	11.3	14.7	1.1	1.5	4.0	4.9	11.5	15.8	29.1	37.2
Net financial items	0.0	-0.3	-1.0	-0.1	-0.1	-0.1	-1.2	-0.1	-0.1	-0.1	-0.1	-0.2	-0.1	-0.1	-0.1
РТР	6.6	12.9	-0.2	2.2	0.2	11.2	13.5	1.0	1.4	4.0	4.9	11.3	15.7	29.0	37.1
Taxes	-1.3	-2.6	0.0	-0.4	0.0	-2.2	-2.7	-0.2	-0.3	-0.8	-1.0	-2.3	-3.1	-5.8	-7.4
Net earnings	5.2	10.3	-0.1	1.8	0.2	8.9	10.8	0.8	1.1	3.2	3.9	9.1	12.6	23.2	29.7
EPS (adj.)	0.43	0.86	0.06	0.13	0.01	0.67	0.88	0.06	0.08	0.24	0.29	0.68	0.93	1.71	2.17
EPS (rep.)	0.43	0.86	-0.01	0.13	0.01	0.67	0.81	0.06	0.08	0.24	0.29	0.68	0.93	1.71	2.17
Key figures	2019	2020	Q1'21	Q2'21	Q3'21	Q4'21	2021	Q1'22e	Q2'22e	Q3'22e	Q4'22e	2022e	2023e	2024e	2025e
Revenue growth-%	57.1 %	29.8 %	3.4 %	3.2 %	-25.4 %	39.4 %	8.9 %	24.4 %	13.6 %	69.0 %	-28.8 %	6.0 %	28.5 %	36.1%	18.8 %
Adjusted EBIT growth-%	-49%	103%	-21%	10%	-92%	70%	11%	28%	-36%	1288%	-56%	-21.7 %	37.3 %	84.2 %	27.7 %
EBITDA-%	23.2 %	34.8 %	13.9 %	27.6 %	8.1 %	58.6 %	35.6 %	15.2 %	17.9 %	35.8 %	38.2 %	28.1%	41.6 %	50.2 %	51.7 %
Adjusted EBIT-%	20.6 %	32.2 %	10.5 %	24.5 %	3.9 %	56.9 %	32.9 %	10.8 %	13.7 %	32.2 %	35.0 %	24.3 %	26.0 %	35.1 %	37.7 %
Net earnings-%	16.6 %	25.2 %	-1.6 %	18.8 %	2.6 %	45.2 %	24.1%	8.2 %	10.6 %	25.4 %	27.7 %	19.1 %	20.6 %	28.0 %	30.1 %

## **Balance sheet**

Assets	2020	2021	2022e	2023e	<b>2024</b> e
Non-current assets	5.3	13.5	18.6	26.3	27.8
Goodwill	0.0	0.0	0.0	0.0	0.0
Intangible assets	2.6	7.2	15.7	24.3	26.2
Tangible assets	2.2	2.6	2.2	1.3	0.8
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	3.0	0.0	0.0	0.0
Other non-current assets	0.6	0.7	0.7	0.7	0.7
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
Current assets	37.9	77.9	74.1	82.6	107
Inventories	0.0	0.0	0.0	0.0	0.0
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	14.2	22.5	16.6	15.2	16.6
Cash and equivalents	23.7	55.4	57.5	67.4	90.2
Balance sheet total	48.4	99.9	101	111	133

Liabilities & equity	2020	2021	2022e	2023e	2024e
Equity	35.4	87.3	94.1	104	124
Share capital	0.1	0.1	0.1	0.1	0.1
Retained earnings	21.5	30.3	37.1	47.0	66.9
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	13.7	56.9	56.9	56.9	56.9
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	2.8	1.8	0.9	0.0	0.0
Deferred tax liabilities	0.0	0.0	0.0	0.0	0.0
Provisions	0.0	0.0	0.0	0.0	0.0
Long term debt	2.8	1.8	0.9	0.0	0.0
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.0	0.0	0.0
Current liabilities	10.2	10.7	6.1	6.7	9.1
Short term debt	0.9	0.9	0.9	0.0	0.0
Payables	9.3	9.8	5.2	6.7	9.1
Other current liabilities	0.0	0.0	0.0	0.0	0.0
Balance sheet total	48.4	99.9	101	111	133


## **DCF** calculation

DCF model	2021	2022e	2023e	<b>2024</b> e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	TERM
EBIT (operating profit)	14.7	11.5	15.8	29.1	37.2	39.3	45.2	48.4	53.2	56.5	58.2	
+ Depreciation	1.2	1.8	9.5	12.5	13.7	11.0	10.9	13.1	12.0	11.6	11.6	
- Paid taxes	-2.7	-2.3	-3.1	-5.8	-7.4	-7.8	-9.0	-9.7	-10.6	-11.3	-11.6	
- Tax, financial expenses	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	-7.8	1.3	2.9	1.1	2.5	2.9	0.9	1.2	0.0	0.0	0.0	
Operating cash flow	5.2	12.3	25.0	36.9	46.0	45.3	47.9	52.9	54.6	56.8	58.1	
+ Change in other long-term liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-12.8	-6.8	-10.6	-10.6	-10.6	-10.8	-11.1	-11.3	-11.4	-11.5	-12.0	
Free operating cash flow	-7.6	5.5	14.4	26.3	35.4	34.5	36.8	41.6	43.2	45.3	46.1	
+/- Other	41.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	33.9	5.5	14.4	26.3	35.4	34.5	36.8	41.6	43.2	45.3	46.1	909
Discounted FCFF		5.2	12.4	20.9	26.1	23.4	23.1	24.2	23.2	22.5	21.1	416
Sum of FCFF present value		619	613	601	580	554	530	507	483	460	438	416
Enterprise value DCF		619										
- Interesting bearing debt		-2.8										
+ Cash and cash equivalents		55.4					<b>C</b> ash flo	wdistribu	ition			
-Minorities		0.0										
-Dividend/capital return		0.0										

2022e-2026e		14%
-------------	--	-----

671

50.1



Wacc

Equity value DCF

Equity value DCF per share

Wall	
Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E)	0.0 %
Cost of debt	5.0 %
Equity Beta	1.10
Market risk premium	4.75%
Liquidity premium	1.00%
Risk free interest rate	2.0 %
Cost of equity	<b>8.2</b> %
Weighted average cost of capital (WACC)	8.2 %

## Summary

Income statement	2019	2020	2021	2022e	2023e	Per share data	2019	2020	2021	2022e	2023e
Revenue	31.6	41.1	44.7	47.4	60.9	EPS (reported)	0.43	0.86	0.81	0.68	0.93
EBITDA	7.4	14.3	15.9	13.3	25.3	EPS (adj.)	0.43	0.86	0.88	0.68	0.93
EBIT	6.5	13.2	14.7	11.5	15.8	OCF / share	-0.04	1.00	0.39	0.92	1.85
PTP	6.6	12.9	13.5	11.3	15.7	FCF / share	-0.25	0.47	2.55	0.41	1.07
Net Income	5.2	10.3	10.8	9.1	12.6	Book value / share	2.19	2.93	6.57	7.03	7.71
Extraordinary items	0.0	0.0	0.0	0.0	0.0	Dividend / share	0.11	0.15	0.17	0.20	0.25
Balance sheet	2019	2020	2021	2022e	2023e	Growth and profitability	2019	2020	2021	2022e	2023e
Balance sheet total	35.9	48.4	99.9	101.1	110.7	Revenue growth-%	57%	30%	9%	6%	28%
Equity capital	26.4	35.4	87.3	94.1	104.0	EBITDA growth-%	568%	95%	11%	<b>-16</b> %	90%
Goodwill	0.0	0.0	0.0	0.0	0.0	EBIT (adj.) growth-%	973%	103%	11%	<b>-22</b> %	37%
Net debt	-15.9	-20.0	-52.6	-55.7	-67.4	EPS (adj.) growth-%	884%	97%	2%	-23%	38%
						EBITDA-%	23.2 %	34.8 %	35.6 %	<b>28.1</b> %	<b>41.6</b> %
Cash flow	2019	2020	2021	2022e	2023e	EBIT (adj.)-%	20.6 %	32.2 %	32.9 %	24.3 %	26.0 %
EBITDA	7.4	14.3	15.9	13.3	25.3	EBIT-%	20.6 %	32.2 %	32.9 %	24.3 %	26.0 %
Change in working capital	-6.5	0.4	-7.8	1.3	2.9	ROE-%	21.5 %	33.5 %	17.6 %	10.0 %	<b>12.7</b> %
Operating cash flow	-0.5	12.1	5.2	12.3	25.0	ROI-%	23.6 %	38.3 %	22.8 %	12.4 %	15.8 %
CAPEX	-2.5	-6.4	-12.8	-6.8	-10.6	Equity ratio	73.5 %	73.2 %	87.4 %	<b>93.1</b> %	93.9 %
Free cash flow	-3.0	5.7	33.9	5.5	14.4	Gearing	-60.2 %	-56.6 %	-60.3 %	-59.2 %	<b>-64.8</b> %

Valuation multiples	2019	2020	2021	2022e	2023e
EV/S	3.9	11.0	10.6	8.3	6.3
EV/EBITDA (adj.)	16.6	31.5	29.9	29.5	15.1
EV/EBIT (adj.)	18.7	34.0	32.3	34.1	24.1
P/E (adj.)	26.4	45.6	45.3	49.6	35.9
P/E	5.2	13.3	6.0	4.8	4.3
Dividend-%	1.0 %	0.4 %	0.4 %	0.6 %	0.8 %

### **Disclaimer and recommendation history**

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy The 12-month risk-adjusted expected shareholder return of the share is very attractive

Accumulate The 12-month risk-adjusted expected shareholder return of the share is attractive

Reduce The 12-month risk-adjusted expected shareholder return of the share is weak

Sell The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder returns between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Inderes' analyst Atte Riikola has a holding of over EUR 50,000 in the target company of the report.

#### Recommendation history (>12 mo)

Date	Recommendation	Target price	Share price
5/30/2017	Accumulate	7.40 €	6.69€
8/17/2017	Buy	7.50 €	6.31€
2/19/2017	Buy	7.50 €	5.90 €
6/4/2018	Buy	8.50 €	7.30 €
8/15/2018	Buy	8.50 €	6.75€
2/13/2019	Accumulate	9.00 €	8.25 €
7/3/2019	Accumulate	10.00 €	9.28 €
8/14/2019	Accumulate	11.50 €	10.65€
12/5/2019	Accumulate	11.50 €	10.15 €
2/16/2020	Accumulate	15.50 €	13.80 €
3/31/2020	Buy	18.00 €	14.80 €
4/21/2020	Accumulate	20.00 €	18.55 €
8/16/2020	Reduce	33.00 €	33.80€
10/27/2020	Accumulate	33.00 €	29.00€
12/10/2020	Accumulate	38.00 €	34.00 €
2/14/2021	Accumulate	50.00 €	45.00 €
4/8/2021	Accumulate	50.00 €	43.75€
5/12/2021	Accumulate	50.00 €	41.30 €
8/16/2021	Accumulate	50.00 €	43.00 €
9/14/2021	Buy	50.00 €	40.00€
11/15/2021	Buy	50.00 €	40.75 €
2/14/2022	Buy	50.00€	33.50 €

## inde res.

Inderes' mission is to connect listed companies and investors. We produce high-quality research and content for the needs of our extensive investor community.

At Inderes we believe that open data is every investor's fundamental right. We guarantee investors' access to award-winning research, insightful video content and an active investor community.

For listed companies we ensure that there is always highquality information available on the company for investors and shareholders for decision making, and that data collected from investors can be utilized by the companies.

Over 100 Finnish listed companies want to serve their shareholders and investors through us by utilizing our company research services, data driven IR services, content creation and consulting.

#### **Inderes Oyj**

Itämerentori 2 FI-00180 Helsinki, Finland +358 10 219 4690

Award-winning research at inderes.fi



THOMSON REUTERS ANALYST AWARDS



2012, 2016, 2017, 2018, 2019, 2020



Mikael Rautanen 2014, 2016, 2017, 2019



Sauli Vilén 2012, 2016, 2018, 2019, 2020



Antti Viljakainen 2014, 2015, 2016, 2018, 2019, 2020





Petri Gostowski

2020



Joni Grönqvist 2019, 2020



Atte Riikola 2020



Erkki Vesola

Olli Koponen 2020



# Research belongs to everyone.